Joakim Dillner

List of Publications by Year
in descending order

329 papers	20,098 citations	15504 65 h-index	14208 128 g-index
338 all docs	338 docs citations	338 times ranked	13908 citing authors

#	Article	IF	Citations
1	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, The, 2014, 383, 524-532.	13.7	1,282
2	Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 2001, 344, 1125-1131.	27.0	800
3	HPV Vaccination and the Risk of Invasive Cervical Cancer. New England Journal of Medicine, 2020, 383, 1340-1348.	27.0	723
4	Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer. New England Journal of Medicine, 2007, 357, 1589-1597.	27.0	701
5	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. International Journal of Cancer, 2009, 124, 516-520.	5.1	557
6	Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine. Journal of the National Cancer Institute, 2001, 93, 284-292.	6.3	540
7	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virusâ€Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPVâ€Naive Women Aged 16â€“26 Years. Journal of Infectious Diseases, 2009, 199, 926-935.	4.0	528
8	Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ: British Medical Journal, 2008, 337, a1754-a1754.	2.3	525
9	Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. Journal of the National Cancer Institute, 2010, 102, 325-339.	6.3	493
10	Type-Specific Persistence of Human Papillomavirus DNA before the Development of Invasive Cervical Cancer. New England Journal of Medicine, 1999, 341, 1633-1638.	27.0	450
11	Screening-Preventable Cervical Cancer Risks: Evidence From a Nationwide Audit in Sweden. Journal of the National Cancer Institute, 2008, 100, 622-629.	6.3	307
12	Seroepidemiology of the human polyomaviruses. Journal of General Virology, 2003, 84, 1499-1504.	2.9	268
13	Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. International Journal of Cancer, 2000, 85, 35-39.	5.1	254
14	Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening. Journal of the National Cancer Institute, 2009, 101, 88-99.	6.3	249
15	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virusâ€Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16â€“26 Years. Journal of Infectious Diseases, 2009, 199, 936-944.	4.0	243
16	A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology, 2013, 445, 224-231.	2.4	243
17	Etiology of Squamous Cell Carcinoma of the Penis. Scandinavian Journal of Urology and Nephrology, 2000, 34, 189-193.	1.4	242
18	International standardization and classification of human papillomavirus types. Virology, 2015, 476, 341-344.	2.4	213

#	Article	IF	Citations
19	The serological response to papillomaviruses. Seminars in Cancer Biology, 1999, 9, 423-430.	9.6	193
20	Are 20 human papillomavirus types causing cervical cancer?. Journal of Pathology, 2014, 234, 431-435.	4.5	190
21	Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin, 2009, 5, 696-704.	2.4	184
22	European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 22-31.	4.5	181
23	European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiology, 2015, 39, S1-S10.	1.9	176
24	Status of implementation and organization of cancer screening in The European Union Member Statesâ€"Summary results from the second European screening report. International Journal of Cancer, 2018, 142, 44-56.	5.1	169
25	Cutaneous Human Papillomaviruses Found in Sunâ€Exposed Skin:Betaâ€papillomavirusSpecies 2 Predominates in Squamous Cell Carcinoma. Journal of Infectious Diseases, 2007, 196, 876-883.	4.0	162
26	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology, 2016, 13, 119-132.	27.6	154
27	Seropositivities to Human Papillomavirus Types 16, 18, or 33 Capsids and to Chlamydia trachomatis Are Markers of Sexual Behavior. Journal of Infectious Diseases, 1996, 173, 1394-1398.	4.0	153
28	Screening and cervical cancer cure: population based cohort study. BMJ: British Medical Journal, 2012, 344, e900-e900.	2.3	153
29	Clinical trials of human papillomavirus vaccines and beyond. Nature Reviews Clinical Oncology, 2013, 10, 400-410.	27.6	147
30	ICTV Virus Taxonomy Profile: Papillomaviridae. Journal of General Virology, 2018, 99, 989-990.	2.9	140
31	Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ: British Medical Journal, 1996, 312, 537-539.	2.3	133
32	Vaccination protects against invasive HPVâ€associated cancers. International Journal of Cancer, 2018, 142, 2186-2187.	5.1	132
33	Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus. Journal of Clinical Microbiology, 2009, 47, 541-546.	3.9	130
34	High Prevalence of Cutaneous Human Papillomavirus DNA on the Top of Skin Tumors but not in â€œStrippedâ€•Biopsies from the Same Tumors. Journal of Investigative Dermatology, 2004, 123, 388-394.	0.7	129
35	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 2018, 15, 292-309.	27.6	129
36	Cervical cancer screening in Europe: Quality assurance and organisation of programmes. European Journal of Cancer, 2015, 51, 950-968.	2.8	127

#	Article	IF	Citations
37	Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study. Journal of the National Cancer Institute, 2013, 105, 469-474.	6.3	123
38	Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. Journal of the National Cancer Institute, 1997, 89, 1293-1299.	6.3	118
39	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clinical Microbiology and Infection, 2021, 27, 1083-1095.	6.0	116
40	Stability over Time of Serum Antibody Levels to Human Papillomavirus Type 16. Journal of Infectious Diseases, 1998, 177, 1710-1714.	4.0	113
41	Global Proficiency Study of Human Papillomavirus Genotyping. Journal of Clinical Microbiology, 2010, 48, 4147-4155.	3.9	104
42	Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ, The, 2014, 348, g130-g130.	6.0	103
43	The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS ONE, 2016, 11, e0147029.	2.5	102
44	Sero-epidemiologal association between human-papillomavirus infection and risk of prostate cancer. , 1998, 75, 564-567.		97
45	A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. Clinical Infectious Diseases, 2018, 66, 339-345.	5.8	96
46	Deep sequencing extends the diversity of human papillomaviruses in human skin. Scientific Reports, 2014, 4, 5807.	3.3	95
47	Nucleic Acid Tests for the Detection of Alpha Human Papillomaviruses. Vaccine, 2012, 30, F100-F106.	3.8	91
48	Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination. American Journal of Epidemiology, 2013, 178, 625-634.	3.4	87
49	Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine, 2020, 23, 100401.	7.1	86
50	Nordic biological specimen banks as basis for studies of cancer causes and control â€“ more than 2 million sample donors, 25 million person years and 100 000 prospective cancers. Acta OncolÃ³gica, 2007, 46, 286-307.	1.8	85
51	ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples. PLoS ONE, 2019, 14, e0222271.	2.5	84
52	Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. Journal of General Virology, 2003, 84, 2105-2109.	2.9	83
53	Association of Varying Number of Doses of Quadrivalent Human Papillomavirus Vaccine With Incidence of Condyloma. JAMA - Journal of the American Medical Association, 2014, 311, 597.	7.4	80
54	Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ: British Medical Journal, 2012, 344, e670-e670.	2.3	79

#	Article	IF	Citations
55	Maternal Herpesvirus Infections and Risk of Acute Lymphoblastic Leukemia in the Offspring. American Journal of Epidemiology, 2003, 158, 207-213.	3.4	78
56	Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Vaccine Journal, 2015, 22, 943-948.	3.1	78
57	Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. BMJ: British Medical Journal, 1995, 311, 1346-1346.	2.3	78
58	Prospective Seroepidemiologic Study of Human Papillomavirus and Other Risk Factors in Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2541-2550.	2.5	77
59	Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses. Journal of Investigative Dermatology, 2013, 133, 2706-2713.	0.7	77
60	Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study.. Journal of General Virology, 1999, 80, 391-398.	2.9	77
61	Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 189-195.	2.5	76
62	Recurrent Respiratory Papillomatosis: HPV Genotypes and Risk of High-Grade Laryngeal Neoplasia. PLoS ONE, 2014, 9, e99114.	2.5	75
63	Severe Acute Respiratory Syndrome Coronavirus 2 RNA in Serum as Predictor of Severe Outcome in Coronavirus Disease 2019: A Retrospective Cohort Study. Clinical Infectious Diseases, 2021, 73, e2995-e3001.	5.8	75
64	Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). British Journal of Cancer, 2020, 123, 510-517.	6.4	74
65	Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison [published erratum appears in J Clin Pathol 1999 Oct;52(10):790]. Journal of Clinical Pathology, 1999, 52, 498-503.	2.0	73
66	HPV type-specific risks of high-grade CIN during 4 years of follow-up: A population-based prospective study. British Journal of Cancer, 2007, 97, 129-132.	6.4	72
67	High throughput sequencing reveals diversity of Human Papillomaviruses in cutaneous lesions. International Journal of Cancer, 2011, 129, 2643-2650.	5.1	72
68	Global Improvement in Genotyping of Human Papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. Journal of Clinical Microbiology, 2014, 52, 449-459.	3.9	72
69	Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. International Journal of Cancer, 1995, 60, 377-382.	5.1	71
70	Cancer Prevention Europe. Molecular Oncology, 2019, 13, 528-534.	4.6	70
71	Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-pointâ€"registry-based follow-up ofthree cohorts from randomized trials. BMJ Open, 2017, 7, e015867.	1.9	67
72	Metagenomic sequencing of â€œHPV-negativeâ€•condylomas detects novel putative HPV types. Virology, 2013, 440, 1-7.	2.4	66

#	Article	IF	Citations
73	Cancer risks after solid organ transplantation and after longâ€term dialysis. International Journal of Cancer, 2017, 140, 1091-1101.	5.1	66
74	Staphylococcus aureusand Squamous Cell Carcinoma of the Skin. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 472-478.	2.5	65
75	Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ: British Medical Journal, 1997, 315, 646-649.	2.3	65
76	Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. Lancet Infectious Diseases, The, 2022, 22, 813-820.	9.1	64
77	Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish Women. Journal of Medical Virology, 2002, 66, 535-541.	5.0	63
78	The 2010 Global Proficiency Study of Human Papillomavirus Genotyping in Vaccinology. Journal of Clinical Microbiology, 2012, 50, 2289-2298.	3.9	63
79	Human Papillomavirus Typing in Reporting of Condyloma. Sexually Transmitted Diseases, 2013, 40, 123-129.	1.7	61
80	Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine, 2018, 36, 4792-4799.	3.8	60
81	A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. , 1999, 80, 489-493.		59
82	Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested caseâ€“control study. Journal of General Virology, 2007, 88, 814-822.	2.9	58
83	A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. , 1996, 68, 54-59.		57
84	Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. American Journal of Obstetrics and Gynecology, 2005, 193, 650-657.	1.3	56
85	Prospective Study of Human Papillomavirus (HPV) Types, HPV Persistence, and Risk of Squamous Cell Carcinoma of the Cervix. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2469-2478.	2.5	56
86	Molecular methods for identification and characterization of novel papillomaviruses. Clinical Microbiology and Infection, 2015, 21, 808-816.	6.0	56
87	Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. Journal of Infectious Diseases, 2016, 213, 199-205.	4.0	56
88	Unbiased Approach for Virus Detection in Skin Lesions. PLoS ONE, 2013, 8, e65953.	2.5	55
89	Cohort Profile: The Janus Serum Bank Cohort in Norway. International Journal of Epidemiology, 2017, 46, dyw027.	1.9	55
90	High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study. PLoS Medicine, 2018, 15, e1002666.	8.4	55

#	Article	IF	Citations
91	In Vivo and In Vitro Intragenomic Rearrangement of TT Viruses. Journal of Virology, 2007, 81, 9346-9356.	3.4	54
92	Prospective study of human papillomavirus and risk of cervical adenocarcinoma. International Journal of Cancer, 2010, 127, 1923-1930.	5.1	54
93	Towards quality and order in human papillomavirus research. Virology, 2018, 519, 74-76.	2.4	54
94	Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine, 2006, 24, S233-S241.	3.8	52
95	Change in Population Prevalences of Human Papillomavirus after Initiation of Vaccination: The High-Throughput HPV Monitoring Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2757-2764.	2.5	51
96	High-Throughput Genotyping of Oncogenic Human Papilloma Viruses with MALDI-TOF Mass Spectrometry. Clinical Chemistry, 2008, 54, 86-92.	3.2	50
97	Prospective Study of Human Papillomavirus Seropositivity and Risk of Nonmelanoma Skin Cancer. American Journal of Epidemiology, 2012, 175, 685-695.	3.4	50
98	Human papillomavirus type 197 is commonly present in skin tumors. International Journal of Cancer, 2015, 136, 2546-2555.	5.1	50
99	Cervical cancer screening in Sweden. European Journal of Cancer, 2000, 36, 2255-2259.	2.8	49
100	Longâ€term HPV typeâ€specific risks of highâ€grade cervical intraepithelial lesions: A 14â€year followâ€up of a randomized primary HPV screening trial. International Journal of Cancer, 2015, 136, 1171-1180.	5.1	48
101	Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. International Journal of Cancer, 2006, 118, 1508-1514.	5.1	47
102	Translational Mini-Review Series on Vaccines:â€¨Monitoring of human papillomavirus vaccination. Clinical and Experimental Immunology, 2007, 148, 199-207.	2.6	47
103	Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. Journal of General Virology, 2008, 89, 2467-2474.	2.9	47
104	Monitoring of human papillomavirus vaccination. Clinical and Experimental Immunology, 2010, 163, 17-25.	2.6	46
105	Next generation sequencing for human papillomavirus genotyping. Journal of Clinical Virology, 2013, 58, 437-442.	3.1	46
106	Genderâ€neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). International Journal of Cancer, 2018, 143, 2299-2310.	5.1	46
107	Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. Journal of Clinical Microbiology, 1996, 34, 3056-3062.	3.9	46
108	Methylation in Predicting Progression of Untreated High-grade Cervical Intraepithelial Neoplasia. Clinical Infectious Diseases, 2020, 70, 2582-2590.	5.8	45

#	Article	IF	Citations
109	Machine Learning for detection of viral sequences in human metagenomic datasets. BMC Bioinformatics, 2018, 19, 336.	2.6	44
110	Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. British Journal of Cancer, 2018, 118, 1377-1381.	6.4	43
111	Antibodies to Merkel Cell Polyomavirus Correlate to Presence of Viral DNA in the Skin. Journal of Infectious Diseases, 2011, 203, 1096-1100.	4.0	42
112	Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine, 2016, 34, 1559-1565.	3.8	42
113	Impact of genderâ€neutral or girlsâ€only vaccination against human papillomavirusâ€"Results of a communityâ€randomized clinical trial (I). International Journal of Cancer, 2018, 142, 949-958.	5.1	42
114	Eradication of human papillomavirus and elimination of HPV-related diseases â€“ scientific basis for global public health policies. Expert Review of Vaccines, 2019, 18, 153-160.	4.4	41
115	Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. BMJ, The, 2016, 352, i276.	6.0	40
116	Impact of HPV vaccination on cervical screening performance: a population-based cohort study. British Journal of Cancer, 2020, 123, 155-160.	6.4	40
117	High risk genital papillomavirus infections arenot spread vertically. , 1999, 9, 23-29.		39
118	Three novel papillomaviruses (HPV109, HPV112 and HPV114) and their presence in cutaneous and mucosal samples. Virology, 2010, 397, 331-336.	2.4	38
119	Prospective Study of HPV16 Viral Load and Risk of In Situ and Invasive Squamous Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 150-158.	2.5	38
120	Targeting Human Papillomavirus to Reduce the Burden of Cervical, Vulvar and Vaginal Cancer and Pre-Invasive Neoplasia: Establishing the Baseline for Surveillance. PLoS ONE, 2014, 9, e88323.	2.5	38
121	Primary human papillomavirus testing in organized cervical screening. Current Opinion in Obstetrics and Gynecology, 2013, 25, 11-16.	2.0	37
122	Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinicalÂtrial. American Journal of Obstetrics and Gynecology, 2017, 216, 264.e1-264.e7.	1.3	37
123	Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden. PLoS Medicine, 2017, 14, e1002414.	8.4	37
124	The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. Journal of Clinical Virology, 2018, 108, 64-71.	3.1	37
125	Human papillomavirus type-specific risk of cervical cancer in a population with high human immunodeficiency virus prevalence: caseâ€"control study. Journal of General Virology, 2011, 92, 2784-2791.	2.9	36
126	Randomised health services studies. International Journal of Cancer, 2012, 131, 2898-2902.	5.1	36

#	Article	IF	Citations
127	The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study. PLoS ONE, 2015, 10, e0134185.	2.5	36
128	Does human papillomavirus-negative condylomata exist?. Virology, 2015, 485, 283-288.	2.4	36
129	Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women. Gynecologic Oncology, 2019, 154, 354-359.	1.4	36
130	Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR. British Journal of Cancer, 2020, 123, 1790-1795.	6.4	36
131	Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles. Journal of General Virology, 2005, 86, 1703-1708.	2.9	35
132	Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assaysâ€"an update. Vaccine, 2006, 24, S193-S200.	3.8	35
133	Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969â€"1989. , 1998, 76, 341-344.		34
134	Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women. International Journal of Cancer, 2000, 87, 232-235.	5.1	34
135	Translational Cancer Research: Balancing Prevention and Treatment to Combat Cancer Globally. Journal of the National Cancer Institute, 2015, 107, 1-5.	6.3	34
136	European Code against Cancer 4th Edition: Infections and Cancer. Cancer Epidemiology, 2015, 39, S120-S138.	1.9	34
137	Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies. Journal of Clinical Virology, 2018, 101, 74-85.	3.1	34
138	Subtype HPV38b[FA125] demonstrates heterogeneity of human papillomavirus type 38. International Journal of Cancer, 2006, 119, 1073-1077.	5.1	33
139	Interactions Between High- and Low-Risk HPV Types Reduce the Risk of Squamous Cervical Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	33
140	Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine, 2018, 36, 3820-3829.	3.8	33
141	Diversity of human papillomaviruses in skin lesions. Virology, 2013, 447, 300-311.	2.4	32
142	Increasing participation in cervical screening by targeting longâ€term nonattenders: Randomized health services study. International Journal of Cancer, 2019, 145, 3033-3039.	5.1	32
143	Cervical cancer caseâ€"control audit: Results from routine evaluation of a nationwide cervical screening program. International Journal of Cancer, 2020, 146, 1230-1240.	5.1	32
144	Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2. Nature Communications, 2021, 12, 3695.	12.8	32

#	Article	IF	Citations
145	Activation of Maternal Epstein-Barr Virus Infection and Risk of Acute Leukemia in the Offspring. American Journal of Epidemiology, 2006, 165, 134-137.	3.4	31
146	Human papillomavirus genotypes in cervical cancers in Mozambique. Journal of General Virology, 2004, 85, 2189-2190.	2.9	30
147	Risk of second cancers after the diagnosis of Merkel cell carcinoma in Scandinavia. British Journal of Cancer, 2011, 104, 178-180.	6.4	30
148	Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort. Journal of Infectious Diseases, 2019, 219, 582-589.	4.0	30
149	Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. Journal of General Virology, 2010, 91, 1840-1848.	2.9	29
150	High-Throughput Monitoring of Human Papillomavirus Type Distribution. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 242-250.	2.5	29
151	Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. Journal of Infectious Diseases, 2020, 222, 948-956.	4.0	29
152	Evaluation of costâ€“precision rations of different strategies for ELISA measurement of serum antibody levels. Journal of Immunological Methods, 2002, 271, 1-15.	1.4	28
153	Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. Journal of General Virology, 2007, 88, 792-802.	2.9	28
154	Organization and quality of HPV vaccination programs in Europe. Vaccine, 2015, 33, 1673-1681.	3.8	28
155	Detection of DNA viruses in prostate cancer. Scientific Reports, 2016, 6, 25235.	3.3	28
156	Evaluation of HPV typeâ€replacement in unvaccinated and vaccinated adolescent femalesâ€”Postâ€hoc analysis of a communityâ€randomized clinical trial (II). International Journal of Cancer, 2018, 142, 2491-2500.	5.1	28
157	Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study. Diagnostic Microbiology and Infectious Disease, 2022, 102, 115595.	1.8	28
158	The Bclâ€xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma. International Journal of Cancer, 2009, 124, 2361-2366.	5.1	27
159	Cervical Cytology Biobanks as a Resource for Molecular Epidemiology. Methods in Molecular Biology, 2011, 675, 279-298.	0.9	27
160	Characterization of two novel cutaneous human papillomaviruses, HPV93 and HPV96. Journal of General Virology, 2007, 88, 1479-1483.	2.9	27
161	Phylogenetically diverse TT virus viremia among pregnant women. Virology, 2012, 432, 427-434.	2.4	26
162	The Swedish Cervical Cytology Biobank: Sample Handling and Storage Process. Biopreservation and Biobanking, 2013, 11, 19-24.	1.0	26

#	Article	IF	Citations
163	Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. Journal of Clinical Virology, 2016, 80, 36-39.	3.1	26
164	Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers. Scientific Reports, 2021, 11, 7614.	3.3	26
165	Performance of Commercial Reverse Line Blot Assays for Human Papillomavirus Genotyping. Journal of Clinical Microbiology, 2012, 50, 1539-1544.	3.9	25
166	Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. Journal of Clinical Virology, 2013, 56, 336-341.	3.1	25
167	Population-based study of screening test performance indices of three human papillomavirus DNA tests. Journal of Medical Virology, 2007, 79, 1169-1175.	5.0	24
168	Registry-based assessment of the status of cervical screening in Sweden. Journal of Medical Screening, 2016, 23, 217-226.	2.3	24
169	Systematic evaluation of SARSâ€CoVâ€2 antigens enables a highly specific and sensitive multiplex serological COVIDâ€19 assay. Clinical and Translational Immunology, 2021, 10, e1312.	3.8	24
170	Prospective study of genital human papillomaviruses and nonmelanoma skin cancer. International Journal of Cancer, 2013, 133, 1840-1845.	5.1	23
171	Bereavement Is Associated with an Increased Risk of HPV Infection and Cervical Cancer: An Epidemiological Study in Sweden. Cancer Research, 2016, 76, 643-651.	0.9	23
172	Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56â€“60. BMJ Open, 2017, 7, e014788.	1.9	23
173	Extension of the viral ecology in humans using viral profile hidden Markov models. PLoS ONE, 2018, 13, e0190938.	2.5	23
174	Human papillomavirus antibody responses among patients with incident cervical carcinoma. Journal of Medical Virology, 1997, 52, 436-440.	5.0	22
175	Herpes simplex virus and human papillomavirus in a populationâ€based caseâ€control study of cervical intraepithelial neoplasia grade IIâ€III. Apmis, 1998, 106, 417-424.	2.0	22
176	Characterization of the complete genomes of Camelus dromedarius papillomavirus types 1 and 2. Journal of General Virology, 2011, 92, 1769-1777.	2.9	22
177	International collaborative proficiency study of Human Papillomavirus type 16 serology. Vaccine, 2012, 30, 294-299.	3.8	22
178	Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study. BMJ Open, 2017, 7, e017070.	1.9	22
179	HPVâ€mRNA and HPVâ€DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. International Journal of Cancer, 2019, 144, 1073-1081.	5.1	22
180	Roadmap for a precision-medicine initiative in the Nordic region. Nature Genetics, 2019, 51, 924-930.	21.4	22

#	Article	IF	Citations
181	Human Serum Antibodies to a Major Defined Epitope of Human Herpesvirus 8 Small Viral Capsid Antigen. Journal of Infectious Diseases, 1999, 179, 1016-1020.	4.0	21
182	Cervical Cytology Biobanking in Europe. International Journal of Biological Markers, 2010, 25, 117-125.	1.8	21
183	Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates. PLoS ONE, 2013, 8, e81171.	2.5	21
184	High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders. British Journal of Cancer, 2018, 118, 138-144.	6.4	21
185	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nature Communications, 2022, 13, 449.	12.8	21
186	A population-based case-control study of human papillomavirus-type-16 seropositivity and incident high-grade dysplasia of the uterine cervix. , 1996, 68, 415-419.		20
187	Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. Journal of Infectious Diseases, 2017, 216, 336-344.	4.0	20
188	Viruses in cancers among the immunosuppressed. International Journal of Cancer, 2017, 141, 2498-2504.	5.1	20
189	Cancer Registry followâ€up for 17Âmillion personâ€years of a nationwide maternity cohort. Cancer Medicine, 2017, 6, 3060-3064.	2.8	20
190	Occurrence of human papillomavirus (HPV) type replacement by sexual riskâ€taking behaviour group: Postâ€hoc analysis of a community randomized clinical trial up to nine years after vaccination (IV). International Journal of Cancer, 2019, 145, 785-796.	5.1	20
191	Human Papillomavirus Infection Determines Prognosis in Cervical Cancer. Journal of Clinical Oncology, 2022, 40, 1522-1528.	1.6	20
192	Ensuring quality in studies linking cancer registries and biobanks. Acta OncolÃ³gica, 2010, 49, 368-377.	1.8	19
193	Follow-up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion:Âa nationwide cohort study. American Journal of Obstetrics and Gynecology, 2017, 216, 48.e1-48.e15.	1.3	19
194	Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. American Journal of Obstetrics and Gynecology, 2020, 222, 253.e1-253.e8.	1.3	19
195	How Many Human Papillomavirus Types Do We Need to Screen For?. Journal of Infectious Diseases, 2021, 223, 1510-1511.	4.0	19
196	Prevention of Human Papillomavirusâ€“Associated Cancers. Seminars in Oncology, 2015, 42, 272-283.	2.2	18
197	Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study. BMJ: British Medical Journal, 2019, 365, l1207.	2.3	18
198	De novo sequence assembly requires bioinformatic checking of chimeric sequences. PLoS ONE, 2020, 15, e0237455.	2.5	18

#	Article	IF	Citations
199	Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs. American Journal of Epidemiology, 2021, 190, 506-514.	3.4	18
200	The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing. Journal of Clinical Virology, 2021, 141, 104902.	3.1	18
201	Preventive human papillomavirus vaccination. Sexually Transmitted Infections, 2002, 78, 4-6.	1.9	17
202	Genotyping of human papillomavirus in triaging of low-grade cervical cytology. American Journal of Obstetrics and Gynecology, 2011, 205, 145.e1-145.e6.	1.3	17
203	Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology. Vaccine Journal, 2012, 19, 449-451.	3.1	17
204	Prospective study of Merkel cell polyomavirus and risk of Merkel cell carcinoma. International Journal of Cancer, 2014, 134, 844-848.	5.1	17
205	Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Caseâ€“Control Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 721-724.	2.5	17
206	Laboratory audit as part of the quality assessment of a primary HPV-screening program. Journal of Clinical Virology, 2016, 75, 33-36.	3.1	17
207	Cervical cancer screening in Sweden 2014-2016. PLoS ONE, 2018, 13, e0209003.	2.5	17
208	A novel human in vitro papillomavirus type 16 positive tonsil cancer cell line with high sensitivity to radiation and cisplatin. BMC Cancer, 2019, 19, 265.	2.6	17
209	Human papillomavirus genotype-specific risks for cervical intraepithelial lesions. Human Vaccines and Immunotherapeutics, 2021, 17, 972-981.	3.3	17
210	Differences in risk for SARS-CoV-2 infection among healthcare workers. Preventive Medicine Reports, 2021, 24, 101518.	1.8	17
211	Invitation strategies and coverage in the population-based cancer screening programmes in the European Union. European Journal of Cancer Prevention, 2019, 28, 131-140.	1.3	16
212	Sequencing detects human papillomavirus in some apparently HPV-negative invasive cervical cancers. Journal of General Virology, 2020, 101, 265-270.	2.9	16
213	Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial. BMJ Open, 2021, 11, e050669.	1.9	16
214	Randomized healthservices study of human papillomavirusâ€based management of lowâ€grade cytological abnormalities. International Journal of Cancer, 2011, 129, 151-159.	5.1	15
215	Viremia during pregnancy and risk of childhood leukemia and lymphomas in the offspring: Nested case-control study. International Journal of Cancer, 2016, 138, 2212-2220.	5.1	15
216	Human papillomavirus types in cervical dysplasia among young HPVâ€vaccinated women: Populationâ€based nested caseâ€“control study. International Journal of Cancer, 2020, 146, 2539-2546.	5.1	15

#	Article	IF	Citations
217	Seroepidemiology of human papillomavirus type 73: A sexually transmitted low-risk virus. International Journal of Cancer, 2000, 85, 353-357.	5.1	14
218	No Risk of Maternal EBV Infection for Childhood Leukemia. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2790-2792.	2.5	14
219	Pre-vaccination seroprevalence of 15 human papillomavirus (HPV) types among women in the population-based Slovenian cervical screening program. Vaccine, 2013, 31, 4935-4939.	3.8	14
220	Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infectious Agents and Cancer, 2014, 9, 4.	2.6	14
221	ViraPipe: scalable parallel pipeline for viral metagenome analysis from next generation sequencing reads. Bioinformatics, 2018, 34, 928-935.	4.1	14
222	Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study. British Journal of Cancer, 2018, 119, 1163-1168.	6.4	14
223	Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma. Scientific Reports, 2020, 10, 9070.	3.3	14
224	Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort. Journal of Infectious Diseases, 2021, 223, 1992-2000.	4.0	14
225	A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) â€“ Study protocol for a randomised controlled trial. Contemporary Clinical Trials, 2021, 101, 106266.	1.8	14
226	Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis. Journal of Medical Microbiology, 2001, 50, 468-471.	1.8	14
227	Cutaneous human papillomavirus 88: Remarkable differences in viral load. International Journal of Cancer, 2008, 122, 477-480.	5.1	13
228	Long-term HPV type-specific risks for ASCUS and LSIL: A 14-year follow-up of a randomized primary HPV screening trial. International Journal of Cancer, 2015, 136, 350-359.	5.1	13
229	Seroprevalences of Antibodies to 11 Human Papillomavirus (HPV) Types Mark Cumulative HPV Exposure. Journal of Infectious Diseases, 2018, 218, 398-405.	4.0	13
230	Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+â€‰plus study. BMC Cancer, 2019, 19, 111.	2.6	13
231	Human papillomavirus types in cervical highâ€grade lesions or cancer among Nordic womenâ€”Potential for prevention. Cancer Medicine, 2019, 8, 839-849.	2.8	13
232	Longâ€term followâ€up of human papillomavirus type replacement among young pregnant Finnish females before and after a communityâ€randomised <scp>HPV</scp> vaccination trial with moderate coverage. International Journal of Cancer, 2020, 147, 3511-3522.	5.1	13
233	Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. American Journal of Preventive Medicine, 2021, 60, 478-487.	3.0	13
234	Antibodies against human papillomavirus type 6 capsids are elevated in men with previous condylomas. Apmis, 1997, 105, 884-888.	2.0	12

#	Article	IF	Citations
235	A Complex Intervention for Workflow Enhancement at the Swedish Cervical Cytology Biobank. Biopreservation and Biobanking, 2014, 12, 69-73.	1.0	12
236	Metagenomic sequencing of expressed prostate secretions. Journal of Medical Virology, 2014, 86, 2042-2048.	5.0	12
237	Risk stratification in cervical cancer screening by complete screening history: Applying bioinformatics to a general screening population. International Journal of Cancer, 2017, 141, 200-209.	5.1	12
238	Transcription of human papillomavirus oncogenes in head and neck squamous cell carcinomas. Vaccine, 2020, 38, 4066-4070.	3.8	12
239	Biobanks Collected for Routine Healthcare Purposes: Build-Up and Use for Epidemiologic Research. Methods in Molecular Biology, 2011, 675, 113-125.	0.9	12
240	Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology. Journal of General Virology, 2005, 86, 65-73.	2.9	12
241	Association of Short-term Air Pollution Exposure With SARS-CoV-2 Infection Among Young Adults in Sweden. JAMA Network Open, 2022, 5, e228109.	5.9	12
242	NordScreen â€“ an interactive tool for presenting cervical cancer screening indicators in the Nordic countries. Acta OncolÃ³gica, 2019, 58, 1199-1204.	1.8	11
243	The Launch of an International Animal Papillomavirus Reference Center. Viruses, 2019, 11, 55.	3.3	10
244	HPV transcription in skin tumors. PLoS ONE, 2019, 14, e0217942.	2.5	10
245	Increase of cervical cancer incidence in Sweden in relation to screening history: population cohort study. Acta OncolÃ³gica, 2020, 59, 988-993.	1.8	10
246	Distribution of HPV Genotypes Differs Depending on Behavioural Factors among Young Women. Microorganisms, 2021, 9, 750.	3.6	10
247	Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care. Scandinavian Journal of Public Health, 2021, 49, 707-712.	2.3	10
248	Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study. Journal of Clinical Virology, 2022, 154, 105237.	3.1	10
249	Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin. Journal of General Virology, 2013, 94, 1096-1103.	2.9	9
250	Clinical validation of full genotyping CLARTÂ® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening. BMC Cancer, 2020, 20, 396.	2.6	9
251	Elimination of HPVâ€“associated oropharyngeal cancers in Nordic countries. Preventive Medicine, 2021, 144, 106445.	3.4	9
252	Misclassifications in human papillomavirus databases. Virology, 2021, 558, 57-66.	2.4	9

#	Article	IF	Citations
253	Organized primary human papillomavirusâ€“based cervical screening: A randomized healthcare policy trial. PLoS Medicine, 2021, 18, e1003748.	8.4	9
254	Prospects for accelerated elimination of cervical cancer. Preventive Medicine, 2021, 153, 106827.	3.4	9
255	Comparison of DNA and RNA sequencing of total nucleic acids from human cervix for metagenomics. Scientific Reports, 2021, 11, 18852.	3.3	9
256	HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2662-2668.	2.5	9
257	Epidemiology of human papillomavirus infection. Scandinavian Journal of Urology and Nephrology, Supplement, 2000, , 194-200.	0.0	9
258	Risk of invasive cervical cancer in relation to management of abnormal Pap smear results. American Journal of Obstetrics and Gynecology, 2009, 201, 188.e1-188.e7.	1.3	8
259	A basis for translational cancer research on aetiology, pathogenesis and prognosis: Guideline for standardised and population-based linkages of biobanks to cancer registries. European Journal of Cancer, 2015, 51, 1018-1027.	2.8	8
260	Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination. Journal of Infectious Diseases, 2017, 216, 966-968.	4.0	8
261	Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia. Aids, 2018, 32, 1475-1484.	2.2	8
262	The HPV16 Genome Is Stable in Women Who Progress to In Situ or Invasive Cervical Cancer: A Prospective Population-Based Study. Cancer Research, 2019, 79, 4532-4538.	0.9	8
263	Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women. International Journal of Cancer, 2020, 147, 440-447.	5.1	8
264	Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study. PLoS ONE, 2020, 15, e0236394.	2.5	8
265	High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers. Journal of Infectious Diseases, 2021, 224, 14-20.	4.0	8
266	Antibodies to SARS-CoV-2 and risk of past or future sick leave. Scientific Reports, 2021, 11, 5160.	3.3	8
267	Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. PLoS Medicine, 2021, 18, e1003588.	8.4	8
268	Human papillomavirus load and genotype analysis improves the prediction of invasive cervical cancer. International Journal of Cancer, 2021, 149, 684-691.	5.1	7
269	Transcription of human papillomaviruses in <scp>nonmelanoma</scp> skin cancers of the immunosuppressed. International Journal of Cancer, 2021, 149, 1341-1347.	5.1	7
270	Different HLAâ€ĐRâ€ĐO haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus typeâ€16 seropositive and seronegative Swedish women. International Journal of Cancer, 1996, 68, 409-414.	5.1	7

#	Article	IF	Citations
271	Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type. PLoS ONE, 2015, 10, e0127444.	2.5	7
272	Human exposome assessment platform. Environmental Epidemiology, 2021, 5, e182.	3.0	7
273	Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?. Expert Reviews in Molecular Medicine, 2004, 6, 1-21.	3.9	6
274	Evaluation of human papillomavirus DNA detection in samples obtained for routine Chlamydia trachomatis screening. Journal of Clinical Virology, 2015, 64, 88-91.	3.1	6
275	Viruses in case series of tumors: Consistent presence in different cancers in the same subject. PLoS ONE, 2017, 12, e0172308.	2.5	6
276	Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data. Vaccine, 2018, 36, 3239-3246.	3.8	6
277	Determinants of the presence of human papillomaviruses in the anal canal of Russian men. Journal of Medical Virology, 2018, 90, 1643-1650.	5.0	6
278	Early detection and prevention. Molecular Oncology, 2019, 13, 591-598.	4.6	6
279	Performance indicators in breast cancer screening in the European Union: A comparison across countries of screen positivity and detection rates. International Journal of Cancer, 2020, 147, 1855-1863.	5.1	6
280	Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening. International Journal of Cancer, 2020, 147, 9-13.	5.1	6
281	Nationwide Rereview of Normal Cervical Cytologies before High-Grade Cervical Lesions or before Invasive Cervical Cancer. Acta Cytologica, 2021, 65, 377-384.	1.3	6
282	Longitudinal biobanks-based study on the joint effects of infections, nutrition and hormones on risk of prostate cancer. Acta OncolÃ³gica, 2016, 55, 839-845.	1.8	5
283	Sourcing of the WHO human papillomavirus type 18 international standards for HPV antibody levels. Journal of Clinical Virology, 2016, 78, 89-92.	3.1	5
284	Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection. Journal of Infectious Diseases, 2018, 218, 927-936.	4.0	5
285	Estimating Total Excess Mortality During a Coronavirus Disease 2019 Outbreak in Stockholm, Sweden. Clinical Infectious Diseases, 2021, 72, e890-e892.	5.8	5
286	Risk for SARS-CoV-2 infection in healthcare workers outside hospitals: A real-life immuno-virological study during the first wave of the COVID-19 epidemic. PLoS ONE, 2021, 16, e0257854.	2.5	5
287	Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. PLoS ONE, 2016, 11, e0156215.	2.5	5
288	Human Papillomavirus (HPV) seroprevalence, cervical HPV prevalence, genotype distribution and cytological lesions in solid organ transplant recipients and immunocompetent women in Sao Paulo, Brazil. PLoS ONE, 2022, 17, e0262724.	2.5	5

#	Article	IF	Citations
289	Differences in transcriptional activity of cutaneous human papillomaviruses. Virus Research, 2008, 137, 213-219.	2.2	4
290	Mutations in human papillomavirus type 16 L1 hypervariable surface-exposed loops affect L2 binding and DNA encapsidation. Journal of General Virology, 2013, 94, 1841-1849.	2.9	4
291	SARSâ€CoVâ€2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden. Journal of Internal Medicine, 2021, 290, 430-436.	6.0	4
292	Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program. International Journal of Cancer, 2021, 149, 2083-2090.	5.1	4
293	Probabilistic classification of antiâ€SARSâ€CoVâ€2 antibody responses improves seroprevalence estimates. Clinical and Translational Immunology, 2022, 11, e1379.	3.8	4
294	Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. Journal of Clinical Virology, 2017, 90, 64-69.	3.1	3
295	Viremia preceding multiple sclerosis: Two nested case-control studies. Virology, 2018, 520, 21-29.	2.4	3
296	Validation of the cobas 6800 human papillomavirus test in primary cervical screening. PLoS ONE, 2021, 16, e0247291.	2.5	3
297	Nonvaccine human papillomavirus genotype common in women with HIV failing cervical precancer treatment. Aids, 2021, 35, 2367-2374.	2.2	3
298	<scp>HPV</scp>â€Positive Status Is an Independent Factor Associated With Sinonasal Inverted Papilloma Recurrence. Laryngoscope, 2022, 132, 1714-1718.	2.0	3
299	Potential SARS-CoV-2 infectiousness among asymptomatic healthcare workers. PLoS ONE, 2021, 16, e0260453.	2.5	3
300	Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses. Journal of Infectious Diseases, 2022, 226, 1195-1199.	4.0	3
301	Human papillomavirus selfâ€sampling with <scp>mRNA</scp> testing benefits routine screening. International Journal of Cancer, 2022, 151, 1989-1996.	5.1	3
302	Editorial. International Journal of Cancer, 2009, 125, vii-vii.	5.1	2
303	Seropositivity to Multiple Anogenital Human Papillomavirus (HPV) Types Is Associated With Current Anogenital HPV Infection, Abnormal Cytology, and Seropositivity for Nongenital HPVs. Journal of Infectious Diseases, 2019, 219, 489-496.	4.0	2
304	Human Papillomavirus Seroprevalence and Seroconversion Among Men Living With HIV: Cohort Study in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 141-148.	2.1	2
305	Comparison of cytology and human papillomavirus-based primary testing in cervical screening programs in the Nordic countries. Journal of Medical Screening, 2021, 28, 464-471.	2.3	2
306	Severe features during outbreak but low mortality observed immediately before and after a Marchâ€“May 2020 COVID-19 outbreak in Stockholm, Sweden. International Journal of Infectious Diseases, 2021, 110, 433-435.	3.3	2

#	Article	IF	Citations
307	Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden. BMJ Open, 2021, 11, e048337.	1.9	2
308	Author's reply to: Human papillomavirus type 197 is not associated with skin tumors. International Journal of Cancer, 2019, 145, 3181-3181.	5.1	1
309	WITHDRAWALâ€"Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe. Tumori, 2020, 106, NP2-NP4.	1.1	1
310	High risk genital papillomavirus infections are not spread vertically. Reviews in Medical Virology, 1999, 9, 23-29.	8.3	1
311	Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women. International Journal of Cancer, 2000, 87, 232-235.	5.1	1
312	Human papillomavirus genotype and prognosis of invasive cervical cancer: A nationwide cohort study.. Journal of Clinical Oncology, 2019, 37, 5525-5525.	1.6	1
313	Shared Environment and Colorectal Cancer: A Nordic Pedigree Registryâ€based Cohort Study. International Journal of Cancer, 0, , .	5.1	1
314	O16.6â€…Pre-Vaccination Seroprevalence of 15 Human Papillomavirus (HPV) Types Among Slovenian Women Screened For Cervical Cancer. Sexually Transmitted Infections, 2013, 89, A58.2-A58.	1.9	0
315	Near full control of human papillomavirus vaccine types. Lancet Infectious Diseases, The, 2015, 15, 1251-1252.	9.1	0
316	Fewer than three doses of HPV vaccine. Lancet Oncology, The, 2015, 16, e422-e423.	10.7	0
317	Some clear answers regarding transmission of genital human papillomavirus. Lancet Infectious Diseases, The, 2019, 19, 227-228.	9.1	0
318	Authorsâ€™ reply. Vaccine, 2020, 38, 5741.	3.8	0
319	A pilot study of risk-stratified cervical cancer screening. Open Research Europe, 0, 1, 84.	2.0	0
320	Decoding our environment: The European Human Exposome Network. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
321	Merkel Cell Polyomavirus: Epidemiology and Clinical Features of Related Cancer. , 2014, , 357-367.		0
322	ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples. , 2019, 14, e0222271.		0
323	ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples. , 2019, 14, e0222271.		0
324	ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples. , 2019, 14, e0222271.		0

#	Article	IF	Citations
325	ViraMiner: Deep learning on raw DNA sequences for identifying viral genomes in human samples. , 2019, 14, e0222271.		0
326	Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study. , 2020, 15, e0236394.		0
327	Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study. , 2020, 15, e0236394.		0
328	Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study. , 2020, 15, e0236394.		0
329	Exposure to polychlorinated compounds and cryptorchidism; A nested case-control study. , 2020, 15, e0236394.		0